Literature DB >> 25549880

Effect on outcomes and exercise performance of anemia in patients with aortic stenosis who underwent transcatheter aortic valve replacement.

Hugo DeLarochellière1, Marina Urena1, Ignacio J Amat-Santos1, Henrique B Ribeiro1, Ricardo Allende1, Louis Laflamme1, Jérôme Laflamme1, Jean-Michel Paradis1, Eric Dumont1, Daniel Doyle1, Siamak Mohammadi1, Robert DeLarochellière1, Melanie Côté1, Vinçent Laroche1, Josep Rodés-Cabau2.   

Abstract

The objectives of this study were to determine the causes and impact of anemia and hemoglobin level on functional status, physical performance, and quality of life in the preprocedural evaluation and follow-up of transcatheter aortic valve replacement (TAVR) candidates. A total of 438 patients who underwent TAVR were included. Anemia was defined as a hemoglobin level <12 g/dl in women and <13 g/dl in men. Before TAVR, anemia was encountered in 282 patients (64.4%). A potential treatable cause of anemia was detected in 90.4% of patients and was attributed to iron deficiency in 53% of them. The occurrence of anemia was an independent predictor of poorer performance in the 6-minute walk test (6MWT), a lower Duke Activity Status Index score, and Kansas City Cardiomyopathy Questionnaires overall, clinical, and social limitation scores (p <0.05 for all). A lower hemoglobin level was associated with a higher prevalence of New York Heart Association class III to IV (p <0.001) and correlated negatively with the results of all functional tests (p <0.02 for all). At follow-up, anemia was found in 62% of patients and was associated with poorer performance in the 6MWT (p = 0.023). A lower hemoglobin level after TAVR was a predictor of poorer New York Heart Association class (p = 0.020) and correlated negatively with the distance walked in the 6MWT (r = -0.191, p = 0.004) and Duke Activity Status Index score (r = -0.158, p = 0.011) at 6-month follow-up. In conclusion, anemia was very common in TAVR candidates and was attributed to iron deficiency in more than half of them. The presence of anemia and lower hemoglobin levels determined poorer functional status before and after the TAVR procedure. These results highlight the importance of implementing appropriate measures for the diagnosis and treatment of this frequent co-morbidity to improve both the accuracy of preprocedural evaluation and outcomes of TAVR candidates.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25549880     DOI: 10.1016/j.amjcard.2014.11.033

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Anemia and risk of periprocedural cerebral injury detected by diffusion-weighted magnetic resonance imaging in patients undergoing transcatheter aortic valve replacement.

Authors:  Stella Ng; Qi-Feng Zhu; Ju-Bo Jiang; Chun-Hui Liu; Jia-Qi Fan; Ye-Ming Xu; Xian-Bao Liu; Jian-An Wang
Journal:  World J Emerg Med       Date:  2022

Review 2.  Multimorbidity in Older Adults with Aortic Stenosis.

Authors:  Brian R Lindman; Jay N Patel
Journal:  Clin Geriatr Med       Date:  2016-02-12       Impact factor: 3.076

3.  Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis.

Authors:  Anette Borger Kvaslerud; Amjad Iqbal Hussain; Andreas Auensen; Thor Ueland; Annika E Michelsen; Kjell Ingar Pettersen; Pål Aukrust; Lars Mørkrid; Lars Gullestad; Kaspar Broch
Journal:  Open Heart       Date:  2018-12-16

4.  Anemia in Patients with Severe Aortic Stenosis.

Authors:  Kazuya Nagao; Tomohiko Taniguchi; Takeshi Morimoto; Hiroki Shiomi; Kenji Ando; Norio Kanamori; Koichiro Murata; Takeshi Kitai; Yuichi Kawase; Chisato Izumi; Makoto Miyake; Hirokazu Mitsuoka; Masashi Kato; Yutaka Hirano; Shintaro Matsuda; Tsukasa Inada; Tomoyuki Murakami; Yasuyo Takeuchi; Keiichiro Yamane; Mamoru Toyofuku; Mitsuru Ishii; Eri Minamino-Muta; Takao Kato; Moriaki Inoko; Tomoyuki Ikeda; Akihiro Komasa; Katsuhisa Ishii; Kozo Hotta; Nobuya Higashitani; Yoshihiro Kato; Yasutaka Inuzuka; Chiyo Maeda; Toshikazu Jinnai; Yuko Morikami; Naritatsu Saito; Kenji Minatoya; Takeshi Kimura
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

5.  Preoperative Anemia and Postoperative Mortality in Patients with Aortic Stenosis Treated with Transcatheter Aortic Valve Implantation (TAVI): A Systematic Review and Meta-Analysis.

Authors:  Zhenqian Lv; Baoguo Zhou; Chunyue Yang; Haiping Wang
Journal:  Med Sci Monit       Date:  2019-09-27

6.  Association of iron deficiency, anaemia, and functional outcomes in patients undergoing edge-to-edge mitral valve repair.

Authors:  Christos Iliadis; Clemens Metze; Maria Isabel Körber; Stephan Baldus; Roman Pfister
Journal:  ESC Heart Fail       Date:  2020-07-03

7.  Comparison of In-Hospital Mortality and Clinical Outcomes Between Patients Aged More Than and Less Than 80 Years Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Mukunthan Murthi; Sujitha Velagapudi; Bharosa Sharma; Olisa Ezegwu; Emmanuel Akuna; Dae Yong Park; Ramtej Atluri; Ufuk Vardar
Journal:  Cureus       Date:  2022-04-27

Review 8.  The safety of exercise for older patients with severe aortic stenosis undergoing conservative management: A narrative review.

Authors:  Satoshi Nashimoto; Tatsuro Inoue; Kazuki Hotta; Yuichi Sugito; Susumu Iida; Atsuhiro Tsubaki
Journal:  Physiol Rep       Date:  2022-04

9.  The Physiological Burden of the 6-Minute Walk Test Compared With Cardiopulmonary Exercise Stress Test in Patients With Severe Aortic Atenosis.

Authors:  Paul Poirier; Marjorie Bastien; Audrey Auclair; Éric Nadreau; Marie-Anick Clavel; Philippe Pibarot; Rodrigo Bagur; Daniel E Forman; Joseph Rodès-Cabau
Journal:  CJC Open       Date:  2021-02-06

Review 10.  Preoperative frailty parameters as predictors for outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis.

Authors:  M S van Mourik; J F Velu; V R Lanting; J Limpens; B J Bouma; J J Piek; J Baan; J P S Henriques; M M Vis
Journal:  Neth Heart J       Date:  2020-05       Impact factor: 2.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.